SCHEMBL14647114

SCHEMBL14647114

O=C(O)c1cc2[nH]c(=O)c3sccc3n2c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CSNK2A1 P68400 4/20 0.43
CSNK2A2 P19784 2/20 0.43
CSNK2B P67870 2/20 0.43
PARP1 P09874 2/20 0.43
GRIK1 P39086 1/20 0.42
GRIA1 P42261 1/20 0.42
SPR P35270 3/20 0.40
MEN1 O00255 2/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPT P10636 2/20 0.39
PKM P14618 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
FEN1 P39748 3/20 0.33
DAO P14920 2/20 0.33
HPGD P15428 1/20 0.32
ERCC5 P28715 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14647240 0.82 PARP1 (0.44) PARP1GRIK1GRIA1SPRMEN1
SCHEMBL14647144 0.75 GRIK1 (0.34) PARP1GRIK1GRIA1MEN1ALDH1A1
SCHEMBL14647112 0.74 PARP1 (0.46) CSNK2A1CSNK2A2CSNK2BPARP1KDM4E
SCHEMBL14647113 0.71 HDAC1 (0.42) PARP1ALDH1A1KDM4EFEN1DAO
SCHEMBL14647133 0.70 PARP1 (0.40) PARP1GRIK1GRIA1ALDH1A1
SCHEMBL31257810 0.64 GRIK1 (0.55) GRIK1GRIA1MEN1ALDH1A1MAPT
SCHEMBL30698069 0.63 POLB (0.39) PARP1GRIK1GRIA1MEN1ALDH1A1
SCHEMBL31751011 0.61 GRIK1 (0.48) PARP1GRIK1GRIA1SPRMEN1
SCHEMBL18689573 0.61 GRIK1 (0.48) GRIK1GRIA1MEN1ALDH1A1MAPT
SCHEMBL1451202 0.60 CSNK2A1 (1.00) CSNK2A1CSNK2A2CSNK2BPARP1SPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2733144-B1 NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY SANTEN PHARMACEUTICAL CO LTD (JP) 2016-01-06 EP disclosed
US-9062061-B2 Compound having PARP inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2015-06-23 US disclosed
US-9062061-B2 Compound having PARP inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2015-06-23 US disclosed
US-9062061-B2 Compound having PARP inhibitory activity SANTEN PHARMACEUTICAL CO., LTD. (JP) 2015-06-23 US disclosed
US-20140243320-A1 NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2014-08-28 US disclosed
US-20140243320-A1 NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2014-08-28 US disclosed
US-20140243320-A1 NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY SANTEN PHARMACEUTICAL CO., LTD. (JP) 2014-08-28 US disclosed
EP-2733144-A1 NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY Santen Pharmaceutical Co., Ltd (JP) 2014-05-21 EP disclosed
WO-2013008872-A1 NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY 参天製薬株式会社 (JP) 2013-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243320-A1 NOVEL COMPOUND HAVING PARP INHIBITORY ACTIVITY PARP1, PARP11, PARP2 CSNK2A1 612/4885CSNK2A2 862/4885CSNK2B 772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.